All In Biotech

Free tool

FAERS Monitor: Targretin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021055 or its brand name (Targretin, Bexarotene). Reports on generic versions are filed under their own applications.

Reports

1,325

Serious

998

75% of reports

Hospitalization

395

Death reported

250

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective113
  • off label use77
  • death76
  • hypothyroidism75
  • hypertriglyceridaemia59
  • disease progression58
  • fatigue50
  • pruritus47
  • malignant neoplasm progression43
  • condition aggravated39
  • nausea37
  • pneumonia34
  • mycosis fungoides30
  • product use in unapproved indication28
  • cutaneous t-cell lymphoma27

Reports by year received

View as table
YearReports
200412
200519
200628
200727
200828
200931
201031
201133
201230
201335
201433
201570
201673
201777
201887
2019104
202097
202184
2022115
202386
202475
202588
202661

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,834 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mycosis fungoidesSignal30601.1419.116,745
cutaneous t-cell lymphomaSignal27347.9238.58,804
hypertriglyceridaemiaSignal59161.6125.89,166
hypothyroidismSignal7537.430.02,616
disease progressionSignal587.86.1338
malignant neoplasm progressionSignal436.75.0202
condition aggravatedSignal392.01.520
pruritus471.91.521
product use in unapproved indication281.81.29
pneumonia341.71.29
death761.41.19
off label use771.41.19
drug ineffective1131.41.111
fatigue501.00.80
nausea370.70.53

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.